Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines.

Guo T, Luna A, Rajapakse VN, Koh CC, Wu Z, Liu W, Sun Y, Gao H, Menden MP, Xu C, Calzone L, Martignetti L, Auwerx C, Buljan M, Banaei-Esfahani A, Ori A, Iskar M, Gillet L, Bi R, Zhang J, Zhang H, Yu C, Zhong Q, Varma S, Schmitt U, Qiu P, Zhang Q, Zhu Y, Wild PJ, Garnett MJ, Bork P, Beck M, Liu K, Saez-Rodriguez J, Elloumi F, Reinhold WC, Sander C, Pommier Y, Aebersold R.

iScience. 2019 Nov 22;21:664-680. doi: 10.1016/j.isci.2019.10.059. Epub 2019 Oct 31.

2.

Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.

Kaur S, Schwartz AL, Jordan DG, Soto-Pantoja DR, Kuo B, Elkahloun AG, Mathews Griner L, Thomas CJ, Ferrer M, Thomas A, Tang SW, Rajapakse VN, Pommier Y, Roberts DD.

Front Oncol. 2019 Oct 1;9:994. doi: 10.3389/fonc.2019.00994. eCollection 2019.

3.

CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.

Rajapakse VN, Luna A, Yamade M, Loman L, Varma S, Sunshine M, Iorio F, Sousa FG, Elloumi F, Aladjem MI, Thomas A, Sander C, Kohn KW, Benes CH, Garnett M, Reinhold WC, Pommier Y.

iScience. 2018 Dec 21;10:247-264. doi: 10.1016/j.isci.2018.11.029. Epub 2018 Dec 12.

4.

SLFN11 Blocks Stressed Replication Forks Independently of ATR.

Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y.

Mol Cell. 2018 Feb 1;69(3):371-384.e6. doi: 10.1016/j.molcel.2018.01.012.

5.

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Tang SW, Thomas A, Murai J, Trepel JB, Bates SE, Rajapakse VN, Pommier Y.

Clin Cancer Res. 2018 Apr 15;24(8):1944-1953. doi: 10.1158/1078-0432.CCR-17-0443. Epub 2018 Feb 1.

6.

TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.

Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.

Mol Cancer Ther. 2017 Nov;16(11):2543-2551. doi: 10.1158/1535-7163.MCT-17-0110. Epub 2017 Aug 11.

7.

Temozolomide in the Era of Precision Medicine.

Thomas A, Tanaka M, Trepel J, Reinhold WC, Rajapakse VN, Pommier Y.

Cancer Res. 2017 Feb 15;77(4):823-826. doi: 10.1158/0008-5472.CAN-16-2983. Epub 2017 Feb 3. Review.

8.

The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition.

Weyemi U, Redon CE, Choudhuri R, Aziz T, Maeda D, Boufraqech M, Parekh PR, Sethi TK, Kasoji M, Abrams N, Merchant A, Rajapakse VN, Bonner WM.

Nat Commun. 2016 Feb 15;7:10711. doi: 10.1038/ncomms10711.

9.

rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R.

Luna A, Rajapakse VN, Sousa FG, Gao J, Schultz N, Varma S, Reinhold W, Sander C, Pommier Y.

Bioinformatics. 2016 Apr 15;32(8):1272-4. doi: 10.1093/bioinformatics/btv701. Epub 2015 Dec 3.

10.

Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity.

Sousa FG, Matuo R, Tang SW, Rajapakse VN, Luna A, Sander C, Varma S, Simon PH, Doroshow JH, Reinhold WC, Pommier Y.

DNA Repair (Amst). 2015 Apr;28:107-15. doi: 10.1016/j.dnarep.2015.01.011. Epub 2015 Feb 11.

11.

Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer.

Reinhold WC, Varma S, Rajapakse VN, Luna A, Sousa FG, Kohn KW, Pommier YG.

Hum Genet. 2015 Jan;134(1):3-11. doi: 10.1007/s00439-014-1482-9. Epub 2014 Sep 12. Review. Erratum in: Hum Genet. 2015 May;134(5):509.

12.

Nonlinear gene cluster analysis with labeling for microarray gene expression data in organ development.

Ehler M, Rajapakse VN, Zeeberg BR, Brooks BP, Brown J, Czaja W, Bonner RF.

BMC Proc. 2011 May 28;5 Suppl 2:S3. doi: 10.1186/1753-6561-5-S2-S3.

13.

RedundancyMiner: De-replication of redundant GO categories in microarray and proteomics analysis.

Zeeberg BR, Liu H, Kahn AB, Ehler M, Rajapakse VN, Bonner RF, Brown JD, Brooks BP, Larionov VL, Reinhold W, Weinstein JN, Pommier YG.

BMC Bioinformatics. 2011 Feb 10;12:52. doi: 10.1186/1471-2105-12-52.

14.

A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis.

Stone JH, Rajapakse VN, Hoffman GS, Specks U, Merkel PA, Spiera RF, Davis JC, St Clair EW, McCune J, Ross S, Hitt BA, Veenstra TD, Conrads TP, Liotta LA, Petricoin EF 3rd; Wegener's Granulomatosis Etanercept Trial Research Group.

Arthritis Rheum. 2005 Mar;52(3):902-10.

Supplemental Content

Loading ...
Support Center